Table 1.
Number of survivors (%) |
||
Age <18 years at baseline and age ≥18 years at 2003FU (Hypothesis 1) | Age ≥18 years at 2003FU (Hypothesis 2) | |
Total n | 2,022 | 8,383 |
Sex | ||
Female | 1,068 (52.8) | 4,252 (50.7) |
Male | 954 (47.2) | 4,131 (49.3) |
Race/ethnicitya | ||
White, non-Hispanic | 1,701 (84.1) | 7,178 (85.6) |
Non-White | 311 (15.4) | 1,172 (14.0) |
Cancer diagnosis | ||
Bone cancer | 20 (1.0) | 738 (8.8) |
CNS | 200 (9.9) | 887 (10.6) |
Hodgkin’s disease | 17 (0.8) | 1,142 (13.6) |
Kidney (Wilms) | 369 (18.2) | 792 (9.4) |
Leukemia | 924 (45.7) | 2,860 (34.1) |
Non-Hodgkin’s lymphoma | 77 (3.8) | 652 (7.8) |
Neuroblastoma | 295 (14.6) | 549 (6.5) |
Soft tissue sarcoma | 120 (5.9) | 763 (9.1) |
Cancer treatmentb | ||
CRT | 528 (26.1) | 2,315 (27.6) |
IT MTX | 894 (44.2) | 2,838 (33.9) |
HD Ara-C | 432 (21.4) | 1,185 (14.1) |
HD MTX | 196 (9.7) | 810 (9.7) |
Spinal radiation | 121 (6.0) | 575 (6.9) |
Brain surgery | 182 (9.0) | 797 (9.5) |
Dexamethasone | 196 (9.7) | 574 (6.8) |
Age at baseline (years) | ||
M (SD) | 14.2 (2.2) | 23.9 (7.7) |
Range | 8–17 | 8–48 |
Age at 2003FU (years) | ||
M (SD) | 22.3 (2.2) | 31.6 (7.5) |
Range | 18–27 | 18–54 |
Age at cancer diagnosis (years) | ||
M (SD) | 2.5 (1.9) | 8.0 (5.8) |
Range | 0–9 | 0–20 |
Note. 2003FU = 2003 follow-up; CNS = central nervous system; CRT = cranial radiation therapy; HD = high dose (≥1,000 mg/m2); IT = intrathecal; MTX = methotrexate.
Missing race information: Hypothesis 1 (n = 10) and Hypothesis 2 (n = 33).
Some survivors are represented in more than one treatment category. Missing treatment information for survivors without medical chart abstractions: Hypothesis 1 (n = 124) and Hypothesis 2 (n = 706).